Search results
Results From The WOW.Com Content Network
Benzodiazepine withdrawal syndrome (BZD withdrawal) is the cluster of signs and symptoms that may emerge when a person who has been taking benzodiazepines as prescribed develops a physical dependence on them and then reduces the dose or stops taking them without a safe taper schedule.
Approximately 15–50% of people who suddenly stop an antidepressant develop antidepressant discontinuation syndrome. [7] [2] [3] [4] The condition is generally not serious, [2] though about half of people with symptoms describe them as severe. [4] Many restart antidepressants due to the severity of the symptoms. [4]
The stopping of antidepressants for example, can lead to antidepressant discontinuation syndrome. With careful physician attention, however, medication prioritization and discontinuation can decrease costs, simplify prescription regimens, decrease risks of adverse drug events and poly-pharmacy, focus therapies where they are most effective, and ...
When stopped abruptly, Wellbutrin can cause withdrawal symptoms. If you develop side effects, it’s important not to make changes to your dosage or stop using Wellbutrin without first talking to ...
Another example of pharmaceutical rebound is a rebound headache from painkillers when the dose is lowered, the medication wears off, or the drug is abruptly discontinued. [ 18 ] In 2022, reports of viral RNA and symptom rebound in people with COVID-19 treated with Paxlovid were published.
Here's why researchers think most people stop taking weight loss drugs within a year. Ken Alltucker, USA TODAY. Updated February 3, 2025 at 1:52 PM.
In medicine, tapering is the practice of gradually reducing the dosage of a medication to reduce or discontinue it. Generally, tapering is done is to avoid or minimize withdrawal symptoms that arise from neurobiological adaptation to the drug.
[12] [13] The decision to stop the trial was controversial because the higher rate of heart failure (HF) in the doxazosin group could have been caused by misdiagnosis due to fluid retention from the medication, or because patients with existing HF stopped their diuretic treatment to switch to doxazosin. However, in the later ASCOT trial, where ...